Athira Pharma, Inc. (NASDAQ: ATHA) Stock Competitors & Peer Comparison
See ATHA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATHA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATHA | $6.75 | -6.12% | 26.6M | -0.70 | -$9.67 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ATHA vs VRTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas VRTX's P/E ratio is 25.45. In terms of profitability, ATHA's ROE is -3.81%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ATHA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
ATHA vs VRNA Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ATHA's ROE is -3.81%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ATHA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ATHA vs REGN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas REGN's P/E ratio is 14.62. In terms of profitability, ATHA's ROE is -3.81%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ATHA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
ATHA vs ARGX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ARGX's P/E ratio is 80.22. In terms of profitability, ATHA's ROE is -3.81%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ATHA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ATHA vs SGEN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ATHA's ROE is -3.81%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ATHA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ATHA vs RVMD Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RVMD's P/E ratio is -26.60. In terms of profitability, ATHA's ROE is -3.81%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ATHA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ATHA vs RVMDW Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, ATHA's ROE is -3.81%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ATHA is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ATHA vs ALNY Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ALNY's P/E ratio is 50.16. In terms of profitability, ATHA's ROE is -3.81%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ATHA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
ATHA vs ONC Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ONC's P/E ratio is 72.91. In terms of profitability, ATHA's ROE is -3.81%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ATHA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ATHA vs ROIV Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ROIV's P/E ratio is -35.69. In terms of profitability, ATHA's ROE is -3.81%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ATHA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ATHA vs INCY Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas INCY's P/E ratio is 15.98. In terms of profitability, ATHA's ROE is -3.81%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ATHA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ATHA vs BNTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BNTX's P/E ratio is -19.72. In terms of profitability, ATHA's ROE is -3.81%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ATHA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ATHA vs INSM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas INSM's P/E ratio is -18.21. In terms of profitability, ATHA's ROE is -3.81%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ATHA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ATHA vs UTHR Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas UTHR's P/E ratio is 19.49. In terms of profitability, ATHA's ROE is -3.81%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ATHA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
ATHA vs MRNA Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MRNA's P/E ratio is -6.83. In terms of profitability, ATHA's ROE is -3.81%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ATHA is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ATHA vs BGNE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ATHA's ROE is -3.81%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ATHA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ATHA vs DNA-WT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ATHA's ROE is -3.81%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ATHA is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ATHA vs NBIX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas NBIX's P/E ratio is 25.49. In terms of profitability, ATHA's ROE is -3.81%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ATHA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
ATHA vs GMAB Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas GMAB's P/E ratio is 20.72. In terms of profitability, ATHA's ROE is -3.81%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ATHA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ATHA vs BBIO Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BBIO's P/E ratio is -22.49. In terms of profitability, ATHA's ROE is -3.81%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ATHA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ATHA vs JAZZ Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, ATHA's ROE is -3.81%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ATHA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ATHA vs ASND Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ASND's P/E ratio is -104.72. In terms of profitability, ATHA's ROE is -3.81%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ATHA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ATHA vs EXEL Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas EXEL's P/E ratio is 16.71. In terms of profitability, ATHA's ROE is -3.81%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ATHA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ATHA vs MDGL Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MDGL's P/E ratio is -43.07. In terms of profitability, ATHA's ROE is -3.81%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ATHA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ATHA vs KRTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ATHA's ROE is -3.81%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ATHA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ATHA vs AXSM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas AXSM's P/E ratio is -62.24. In terms of profitability, ATHA's ROE is -3.81%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ATHA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ATHA vs ARWR Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ARWR's P/E ratio is -39.78. In terms of profitability, ATHA's ROE is -3.81%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ATHA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ATHA vs BMRN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BMRN's P/E ratio is 28.98. In terms of profitability, ATHA's ROE is -3.81%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ATHA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ATHA vs RNAM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ATHA's ROE is -3.81%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ATHA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ATHA vs TECH Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas TECH's P/E ratio is 36.91. In terms of profitability, ATHA's ROE is -3.81%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ATHA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ATHA vs KRYS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas KRYS's P/E ratio is 47.03. In terms of profitability, ATHA's ROE is -3.81%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ATHA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ATHA vs SMMT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas SMMT's P/E ratio is -8.19. In terms of profitability, ATHA's ROE is -3.81%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ATHA is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ATHA vs CYTK Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CYTK's P/E ratio is -13.83. In terms of profitability, ATHA's ROE is -3.81%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ATHA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ATHA vs HALO Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas HALO's P/E ratio is 17.64. In terms of profitability, ATHA's ROE is -3.81%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ATHA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ATHA vs RXDX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ATHA's ROE is -3.81%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ATHA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
ATHA vs ABVX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ABVX's P/E ratio is -67.09. In terms of profitability, ATHA's ROE is -3.81%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ATHA is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ATHA vs IONS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas IONS's P/E ratio is -32.53. In terms of profitability, ATHA's ROE is -3.81%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ATHA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ATHA vs NUVL Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ATHA's ROE is -3.81%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ATHA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ATHA vs KYMR Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas KYMR's P/E ratio is -31.18. In terms of profitability, ATHA's ROE is -3.81%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ATHA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ATHA vs CRNX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ATHA's ROE is -3.81%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ATHA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ATHA vs PRAX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas PRAX's P/E ratio is -23.62. In terms of profitability, ATHA's ROE is -3.81%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ATHA is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
ATHA vs ALKS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ALKS's P/E ratio is 55.51. In terms of profitability, ATHA's ROE is -3.81%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ATHA is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ATHA vs IMGN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ATHA's ROE is -3.81%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ATHA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ATHA vs PTGX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas PTGX's P/E ratio is -74.90. In terms of profitability, ATHA's ROE is -3.81%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ATHA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ATHA vs SYRE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas SYRE's P/E ratio is -48.10. In terms of profitability, ATHA's ROE is -3.81%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ATHA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ATHA vs TGTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas TGTX's P/E ratio is 19.16. In terms of profitability, ATHA's ROE is -3.81%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ATHA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ATHA vs BPMC Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ATHA's ROE is -3.81%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ATHA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ATHA vs APGE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas APGE's P/E ratio is -31.01. In terms of profitability, ATHA's ROE is -3.81%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ATHA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ATHA vs IMVT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas IMVT's P/E ratio is -15.01. In terms of profitability, ATHA's ROE is -3.81%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ATHA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ATHA vs CERE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CERE's P/E ratio is -16.47. In terms of profitability, ATHA's ROE is -3.81%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ATHA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ATHA vs PCVX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas PCVX's P/E ratio is -8.07. In terms of profitability, ATHA's ROE is -3.81%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ATHA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ATHA vs MTSR Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ATHA's ROE is -3.81%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ATHA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ATHA vs IBRX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas IBRX's P/E ratio is -8.22. In terms of profitability, ATHA's ROE is -3.81%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ATHA is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ATHA vs RYTM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RYTM's P/E ratio is -33.91. In terms of profitability, ATHA's ROE is -3.81%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ATHA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ATHA vs MIRM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MIRM's P/E ratio is -8.39. In terms of profitability, ATHA's ROE is -3.81%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ATHA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ATHA vs COGT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas COGT's P/E ratio is -19.17. In terms of profitability, ATHA's ROE is -3.81%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ATHA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
ATHA vs MRUS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ATHA's ROE is -3.81%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ATHA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ATHA vs ACLX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ATHA's ROE is -3.81%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ATHA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ATHA vs RETA Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RETA's P/E ratio is -66.29. In terms of profitability, ATHA's ROE is -3.81%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ATHA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
ATHA vs ERAS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ERAS's P/E ratio is -20.29. In terms of profitability, ATHA's ROE is -3.81%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ATHA is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
ATHA vs CGON Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CGON's P/E ratio is -31.55. In terms of profitability, ATHA's ROE is -3.81%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ATHA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ATHA vs XENE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas XENE's P/E ratio is -14.00. In terms of profitability, ATHA's ROE is -3.81%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ATHA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ATHA vs BLTE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas BLTE's P/E ratio is -84.72. In terms of profitability, ATHA's ROE is -3.81%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ATHA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ATHA vs PTCT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas PTCT's P/E ratio is -32.53. In terms of profitability, ATHA's ROE is -3.81%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ATHA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ATHA vs CNTA Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ATHA's ROE is -3.81%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ATHA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ATHA vs LGND Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas LGND's P/E ratio is 35.67. In terms of profitability, ATHA's ROE is -3.81%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ATHA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ATHA vs SRRK Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas SRRK's P/E ratio is -13.63. In terms of profitability, ATHA's ROE is -3.81%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ATHA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ATHA vs CDTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ATHA's ROE is -3.81%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ATHA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ATHA vs ABCM Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ATHA's ROE is -3.81%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ATHA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ATHA vs ISEE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ATHA's ROE is -3.81%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ATHA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ATHA vs TVTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas TVTX's P/E ratio is -257.64. In terms of profitability, ATHA's ROE is -3.81%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ATHA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ATHA vs APLS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas APLS's P/E ratio is 38.35. In terms of profitability, ATHA's ROE is -3.81%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ATHA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ATHA vs TERN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas TERN's P/E ratio is -51.41. In terms of profitability, ATHA's ROE is -3.81%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ATHA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ATHA vs DFTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas DFTX's P/E ratio is N/A. In terms of profitability, ATHA's ROE is -3.81%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ATHA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
ATHA vs MANE Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MANE's P/E ratio is -35.45. In terms of profitability, ATHA's ROE is -3.81%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ATHA is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ATHA vs FOLD Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ATHA's ROE is -3.81%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ATHA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ATHA vs CRSP Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CRSP's P/E ratio is -9.15. In terms of profitability, ATHA's ROE is -3.81%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ATHA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ATHA vs AKRO Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ATHA's ROE is -3.81%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ATHA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ATHA vs EWTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas EWTX's P/E ratio is -25.06. In terms of profitability, ATHA's ROE is -3.81%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ATHA is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ATHA vs ALPN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ATHA's ROE is -3.81%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ATHA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ATHA vs CAI Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CAI's P/E ratio is -85.97. In terms of profitability, ATHA's ROE is -3.81%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ATHA is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ATHA vs DNTH Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas DNTH's P/E ratio is -25.30. In terms of profitability, ATHA's ROE is -3.81%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ATHA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ATHA vs ACAD Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ACAD's P/E ratio is 12.45. In terms of profitability, ATHA's ROE is -3.81%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ATHA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ATHA vs DYN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas DYN's P/E ratio is -7.96. In terms of profitability, ATHA's ROE is -3.81%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ATHA is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
ATHA vs OPT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas OPT's P/E ratio is -1.52. In terms of profitability, ATHA's ROE is -3.81%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ATHA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ATHA vs MRTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ATHA's ROE is -3.81%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ATHA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ATHA vs VKTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas VKTX's P/E ratio is -8.42. In terms of profitability, ATHA's ROE is -3.81%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ATHA is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ATHA vs CELC Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CELC's P/E ratio is -21.09. In terms of profitability, ATHA's ROE is -3.81%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ATHA is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ATHA vs CPRX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ATHA's ROE is -3.81%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ATHA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ATHA vs ELVN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ELVN's P/E ratio is -31.58. In terms of profitability, ATHA's ROE is -3.81%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ATHA is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ATHA vs RYZB Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ATHA's ROE is -3.81%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ATHA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ATHA vs DNLI Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas DNLI's P/E ratio is -8.18. In terms of profitability, ATHA's ROE is -3.81%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ATHA is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ATHA vs CBAY Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ATHA's ROE is -3.81%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ATHA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
ATHA vs NAMSW Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, ATHA's ROE is -3.81%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ATHA is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ATHA vs ADPT Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas ADPT's P/E ratio is -41.74. In terms of profitability, ATHA's ROE is -3.81%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, ATHA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ATHA vs LEGN Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas LEGN's P/E ratio is -28.34. In terms of profitability, ATHA's ROE is -3.81%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ATHA is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ATHA.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ATHA vs SWTX Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ATHA's ROE is -3.81%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ATHA is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
ATHA vs NAMS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas NAMS's P/E ratio is -19.01. In terms of profitability, ATHA's ROE is -3.81%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ATHA is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
ATHA vs RCUS Comparison July 2026
Athira Pharma, Inc. (NASDAQ: ATHA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATHA stands at 26.6M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ATHA is priced at $6.75 on the NASDAQ, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATHA currently has a P/E ratio of -0.70, whereas RCUS's P/E ratio is -8.56. In terms of profitability, ATHA's ROE is -3.81%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ATHA is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for ATHA.Check RCUS's competition here